Immunization

Vaccination discussion continues with a focus on navigating patient concerns and potential adverse effects to vaccine administration.

Infants of fully vaccinated mothers had fewer cases of hospitalization from COVID-19 than those unvaccinated.

William J. Muller, MD, PhD, discusses COVID-19 vaccinations for children of all ages and describes what is on the horizon for RSV.

When it comes to the COVID-19 vaccine, independent pharmacies are being set up to fail by federal health partners.

This National Immunization Awareness Month, prepare your pharmacy to offer important vaccines.

Pfizer-BioNTech hopes booster can be available for use this fall.

Mitchel Rothholz, RPh, MBA, leads panelists in a conversation regarding strategies to manage increased pharmacist workload in anticipation of the coming flu season.

A panel of experts open a discussion surrounding influenza vaccines amid patient vaccine hesitancy.

Domestic production to begin at Michigan-based pharmaceutical maker.

The FDA has granted Emergency Use Authorization EUA of the Jynneos vaccine for pediatric patients <18 years who are at high risk of monkeypox infection.

The latest guidance for when to administer the COVID-19 vaccine to patients aged 6 months and older.

Adults aged 18 and older are eligible to receive the vaccine.

Purchase follows FDA recommendation to include Omicron component in boosters.

The preferential recommendation is built on research and real-world data

The FDA approved the pneumococcal 15-valent conjugate vaccine for the prevention of invasive pneumococcal disease in infants and children.

The FDA announced the EUA of both Moderna and Pfizer-BioNTech COVID-19 vaccines for use in children aged 6 months and older.

The program administered 60 vaccines to patients referred by their primary care physicians.

A majority of survey respondents were willing to receive a COVID-19 vaccine.

If authorized, it will be the fourth COVID-19 vaccine available in the Untied States.

GSK plc announced FDA approval of the PRIORIX vaccine for prevention of measles, mumps, and rubella.

During COVID-19, pharmacy technicians helped keep immunization programs running.

Results address the concern that COVID-19 vaccination might not be effective among those living with HIV.

Pfizer-BioNTech reports strong immune response, high efficacy, and favorable safety in third dose of the COVID-19 vaccine.

Research suggests that COVID-19 vaccination may serve a therapeutic effect, possibly reducing the risk of developing long COVID when administered to those currently infected.

The vaccine also prevented nearly 9 million symptomatic cases.